M. Cacho

发表

Intercalators as anticancer drugs.

M. Braña, B de Pascual-Teresa, M. Cacho, 2001, Current pharmaceutical design.

Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons.

N. Osheroff, J. Berger, B. Bax, 2018, ACS infectious diseases.

Mycobacterium tuberculosis Gyrase Inhibitors as a New Class of Antitubercular Drugs

J. Lavandera, David Barros, Lluís Ballell, 2015, Antimicrobial Agents and Chemotherapy.

DNA sequence recognition by bispyrazinonaphthalimides antitumor agents.

C. Bailly, C. Tardy, M. Braña, 2003, Biochemistry.

Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides.

C. Bailly, P. Colson, C. Houssier, 2003, Biochemistry.

Exploring the SAR of the β-Ketoacyl-ACP Synthase Inhibitor GSK3011724A and Optimization around a Genotoxic Metabolite.

Robert H Bates, Fraser Cunningham, C. Chung, 2020, ACS infectious diseases.

Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.

Olivier Lozach, Laurent Meijer, L. Meijer, 2005, Journal of medicinal chemistry.

Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions

Robert H Bates, M. Vieth, P. Hipskind, 2022, ACS infectious diseases.

Bimodal actions of a naphthyridone/aminopiperidine-based antibacterial that targets gyrase and topoisomerase IV.

N. Osheroff, K. Neuman, M. Cacho, 2019, Biochemistry.

New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties.

J. Lacal, Mónica Báñez-Coronel, M. Braña, 2004, Journal of medicinal chemistry.

Synthesis, biological evaluation and DNA binding properties of novel mono and bisnaphthalimides.

C. Bailly, M. Braña, C. Carrasco, 2003, Organic & biomolecular chemistry.

Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities.

F. Cuttitta, Alfredo Martínez, Miguel Julián, 2005, European journal of medicinal chemistry.

Mycobacterium tuberculosis Decaprenylphosphoryl-β-D-ribose Oxidase inhibitors: expeditious reconstruction of sub-optimal hits into a series with potent in vivo activity.

I. Wall, G. Burley, M. Cacho, 2020, Journal of medicinal chemistry.

Optimization of hydantoins as potent antimycobacterial decaprenylphosphoryl-β-D-ribose oxidase (DprE1) inhibitors.

Robert H Bates, Fraser Cunningham, P. Van der Veken, 2020, Journal of medicinal chemistry.

Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.

Christophe M. L. Vande Velde, Robert H Bates, Fraser Cunningham, 2018, Journal of medicinal chemistry.

Tetrahydropyrazolo[1,5-a]Pyrimidine-3-Carboxamide and N-Benzyl-6′,7′-Dihydrospiro[Piperidine-4,4′-Thieno[3,2-c]Pyran] Analogues with Bactericidal Efficacy against Mycobacterium tuberculosis Targeting MmpL3

N. Loman, C. Constantinidou, M. Pallen, 2013, PloS one.

Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors.

G. Burley, M. Cacho, Benjamin C Whitehurst, 2020, Bioorganic & medicinal chemistry letters.

Stereoselective synthesis of the cyclic ether core of (+)-laurenyne

Claire Wilson, S. Swallow, M. Cacho, 2004 .

Stereoselective Synthesis of the Cyclic Ether Core of (+)-Laurenyne.

Claire Wilson, S. Swallow, M. Cacho, 2005 .

Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis.

Katrina A. Badiola, M. Todd, P. Rutledge, 2018, Journal of medicinal chemistry.